MD, MHS
Professor, Hematology
Clinic Medical Director, Malignant Hematology
UNC-Chapel Hill
Clinical Research
Meet Sascha Tuchman
Area of Interest
I am a board-certified hematologist and medical oncologist and I divide my time between clinical care and clinical research. I study and treat all forms of plasma cell disorders but have a special research interest in amyloidosis and senior and/or frail patients with multiple myeloma.
I lead the multiple myeloma and amyloidosis group at the University of North Carolina – Chapel Hill. I have years of experience in managing patients and leading clinical trials in these diseases. I head the teams that manage these patients clinically, collect clinical data, analyze data, and prepare abstracts for conference submissions and manuscript publications. I also mentor trainees with an interest in these disorders and several of my former mentees are pursuing training for careers in academic hematology and oncology.
I sit on expert groups that conduct research in and formulate guidelines for managing plasma cell disorders, and I participate in national cooperative groups such as the ALLIANCE multiple myeloma committee and subcommittee for myeloma in the elderly.
Awards and Honors
- Selection as Eugene Stead Teaching Attending Physician, Duke University Medical Center, 2012
- Burroughs Wellcome Foundation Travel Award, 2010
- American Society of Hematology Travel Award, 2009
- American Society of Clinical Oncology Merit Award, 2009
- Travel Award, American Society of Hematology, 2009
- Summa cum laude honors, Georgetown University School of Medicine, 2003
- Golden Key National Honor Society, Tufts University, 1996
- Cum laude honors at graduation, Tufts University, 1996
- J. William Fulbright Grant, Humboldt University, Berlin, Germany, 1996
News and Stories
Improved multiple myeloma therapies help patients live longer, better lives
March is Multiple Myeloma Awareness Month, an opportunity to shed light on a disease that accounts for approximately 10% of all blood cancers. Treatment options for multiple myeloma have expanded in recent years, leading to better patient outcomes and longer survival rates.
Multiple myeloma is a silent invader
Multiple myeloma is cancer of the immune system. Oncologist Sascha Tuchman, MD, MHS, shares what you need to know about the condition and treatment.
